| 25.93 0.02 (0.08%) | 04-26 12:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.32  |
1-year : | 35.69 |
| Resists | First : | 28.53 |
Second : | 30.55 |
| Pivot price | 26.78 |
|||
| Supports | First : | 25.25 | Second : | 21 |
| MAs | MA(5) : | 26.36  |
MA(20) : | 27.2 |
| MA(100) : | 39.31 |
MA(250) : | 32.61 |
|
| MACD | MACD : | -1.9 |
Signal : | -2.3 |
| %K %D | K(14,3) : | 21.1 |
D(3) : | 28 |
| RSI | RSI(14): 34 |
|||
| 52-week | High : | 53.38 | Low : | 22.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SMLR ] has closed above bottom band by 31.7%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.62 - 26.77 | 26.77 - 26.89 |
| Low: | 25.43 - 25.61 | 25.61 - 25.76 |
| Close: | 25.64 - 25.91 | 25.91 - 26.14 |
Semler Scientific, Inc. provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Tue, 23 Apr 2024
Semler Scientific to Report First Quarter Financial Results and Host Conference Call on May 7, 2024 - Yahoo Finance Australia
Tue, 23 Apr 2024
What Kind Of Shareholders Hold The Majority In Semler Scientific, Inc.'s (NASDAQ:SMLR) Shares? - Yahoo Movies Canada
Wed, 17 Apr 2024
Many Still Looking Away From Semler Scientific, Inc. (NASDAQ:SMLR) - Simply Wall St
Wed, 06 Mar 2024
Is Weakness In Semler Scientific, Inc. (NASDAQ:SMLR) Stock A Sign That The Market Could be Wrong Given Its Strong ... - Simply Wall St
Tue, 05 Mar 2024
Semler Scientific Reports Fourth Quarter and Full Year 2023 Financial Results - PR Newswire
Tue, 13 Feb 2024
Semler Scientific Offers Great Potential, But Don't Overlook The Risks (NASDAQ:SMLR) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 22.2 (%) |
| Held by Institutions | 52.3 (%) |
| Shares Short | 216 (K) |
| Shares Short P.Month | 215 (K) |
| EPS | 2.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.43 |
| Profit Margin | 30.1 % |
| Operating Margin | 17.6 % |
| Return on Assets (ttm) | 20.4 % |
| Return on Equity (ttm) | 32.2 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.69 |
| EBITDA (p.s.) | 3.31 |
| Qtrly Earnings Growth | 31.5 % |
| Operating Cash Flow | 21 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | 9.85 |
| PEG Ratio | 0 |
| Price to Book value | 2.48 |
| Price to Sales | 2.67 |
| Price to Cash Flow | 8.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|